Last reviewed · How we verify
NBP606
NBP606 is a small molecule that targets the SGLT2 receptor.
NBP606 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | NBP606 |
|---|---|
| Sponsor | SK Chemicals Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, NBP606 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as empagliflozin and canagliflozin.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
- Hypotension
Key clinical trials
- Immunogenicity and Safety Study of NBP606 in Healthy Infants (PHASE3)
- Immunogenicity and Safety Study of NBP606 in Healthy Toddlers (PHASE3)
- Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NBP606 CI brief — competitive landscape report
- NBP606 updates RSS · CI watch RSS
- SK Chemicals Co., Ltd. portfolio CI